Adaptive platform trials for rare disease populations
BANDICOOT is an international adaptive platform trial (APT) designed to identify effective therapies that improve health outcomes for critically ill children receiving a haematopoetic stem cell transplant (HCT). Building
on extensive engagement with patients, their parents, and clinicians, we will launch 3 trial domains focused on exercise, nutritional supplementation, and the gut microbiome